市场调查报告书
商品编码
1422881
2024-2032 年左心耳封堵器材市场(依产品(心内膜 LAA 器材、心外膜 LAA 器材)、最终用户(医院、门诊手术中心等)及地区)Left Atrial Appendage Closure Devices Market by Product (Endocardial LAA Devices, Epicardial LAA Devices), End User (Hospitals, Ambulatory Surgery Centers, and Others), and Region 2024-2032 |
2023年,全球左心耳封堵器市场规模达到15亿美元。展望未来, IMARC Group预计到2032年市场规模将达到63亿美元,2024-2032年复合年增长率(CAGR)为16.85%。心房颤动 (AFib) 盛行率不断上升、易患心血管疾病 (CVD) 的老年人口不断增加,以及持续的产品进步和创新是推动市场发展的一些关键因素。
左心耳阻塞装置 (LAAC) 是植入心臟的医疗装置,用于降低非瓣膜性心房颤动 (AFib) 患者中风的风险。左心耳 (LAA) 是位于心臟肌壁中的小袋状结构,可能是血栓的来源,导致 AFib 患者中风。 LAAC 装置旨在永久封闭左心耳,以防止血栓形成并降低中风风险。它们透过微创 (MI) 手术植入,通常使用透过手臂或腹股沟区域的小切口插入的导管。这些设备在无法服用抗凝血药物或因这些药物而出现出血併发症的高风险的 AFib 患者中广泛流行。
由于不健康的饮食习惯、吸烟、饮酒和久坐的生活方式的广泛采用,心房颤动的盛行率不断上升,这主要推动了全球市场的成长。除此之外,容易患心血管疾病(CVD)的老年人口不断增加、消费者对 AFib 相关风险和併发症的担忧不断升级,以及对替代治疗方案可用性的认识不断增强,都在推动市场成长。此外,闭合装置在产品安全性和有效性方面的重大技术进步,以及对开发微创闭合装置以减少恢復时间和提高患者舒适度的大力重视,都为市场带来了有利可图的成长机会。同时,电生理学程序的出现,加上介入治疗和诊断途径的显着改进,正在促进市场的成长。除此之外,医疗基础设施的快速扩张、医疗服务的普及、微创封堵器的普及、各国政府发起的众多宣传活动以及报销政策的出台都有助于市场扩张。 。此外,广泛的产品创新研发(R&D)活动、心房介入产品批准数量的增加、临床试验数量的增加以及机器人辅助闭合装置等新技术的采用,都对市场产生了积极影响生长。
The global left atrial appendage closure devices market size reached US$ 1.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.3 Billion by 2032, exhibiting a growth rate (CAGR) of 16.85% during 2024-2032. The escalating prevalence of atrial fibrillation (AFib), the growing geriatric population prone to cardiovascular disorders (CVDs), and ongoing product advancements and innovations represent some of the key factors driving the market.
Left atrial appendage closure devices (LAAC) are medical devices that are implanted in the heart to lower the risk of stroke in patients with non-valvular atrial fibrillation (AFib). The left atrial appendage (LAA) is a small pouch-like structure located in the muscle wall of the heart, which can be a source of blood clots, leading to stroke in AFib patients. LAAC devices are designed to permanently close off the LAA to prevent the formation of blood clots and reduce the risk of stroke. They are implanted via minimally invasive (MI) procedures, typically using a catheter that is inserted through a small incision placed in the arm or groin region. These devices are widely popular among AFib patients who cannot take anticoagulant medications or are at high risk of bleeding complications from these medications.
The rising prevalence of AFib, on account of the widespread adoption of unhealthy eating habits, smoking, drinking, and sedentary lifestyles, is primarily driving the global market growth. Besides this, the growing geriatric population prone to cardiovascular disorders (CVDs), the escalating consumer concerns regarding risks and complications associated with AFib, and the expanding awareness about the availability of alternative treatment options are impelling the market growth. Moreover, significant technological advancements in closure devices in terms of the safety and efficacy of the product and the intensive emphasis on developing minimally invasive closure devices to reduce recovery time and improve patient comfort are presenting remunerative growth opportunities for the market. Concurrent with this, the advent of electrophysiology procedures, combined with considerable improvements in interventional treatments and the diagnosis pathway, is contributing to the market growth. In addition to this, rapid expansion in the healthcare infrastructure, better access to healthcare services, the surging popularity of minimally invasive closure devices, the launch of numerous awareness campaigns by governments of various countries, and the availability of reimbursement policies are aiding in market expansion. Furthermore, extensive research and development (R&D) activities for product innovation, a rising number of atrial intervention product approvals, an increasing number of clinical trials, and the adoption of new technologies, such as robotic-assisted closure devices, are positively impacting the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global left atrial appendage closure devices market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product, and end user.
Endocardial LAA Devices
Epicardial LAA Devices
The report has provided a detailed breakup and analysis of the left atrial appendage closure devices market based on the product. This includes endocardial LAA devices and epicardial LAA devices. According to the report, endocardial LAA devices represented the largest segment.
Hospitals
Ambulatory Surgery Centers
Others
A detailed breakup and analysis of the left atrial appendage closure devices market based on the end user has also been provided in the report. This includes hospitals, ambulatory surgery centers, and others. According to the report, hospitals accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for left atrial appendage closure devices. Some of the factors driving the North America left atrial appendage closure devices market included a growing number of atrial fibrillation (Afib) cases, a rise in the geriatric population, and innovative technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global left atrial appendage closure devices market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, AtriCure Inc., Boston Scientific Corporation, Cardia Inc., Lepu Medical Technology (Beijing) Co. Ltd., LifeTech Scientific, etc.